磷霉素对肠球菌体外抗菌活性的实验研究

Antimicrobial Activity of Fosfomycin and Other Antibiotics against Enterococcus

目的:研究磷霉素对肠球菌的体外抗菌活性,并与8种常用抗菌药进行对比,为临床药物选择提供参考。方法:收集2018年1月~12月患者临床标本中分离的肠球菌187株,用全自动细菌鉴定药敏分析仪测定8种抗菌药对肠球菌的体外抗菌活性,采用纸片扩散(K-B)测定磷霉素的抗菌活性,结果以CLSI 2017版标准判断;应用WHONET 5.6软件分析分离病原菌的分布和耐药情况。结果:在187株肠球菌中有屎肠球菌97株,粪肠球菌86株,其他肠球菌4株。未见万古霉素(天然耐药菌株除外)、替考拉宁耐药的菌株,对磷霉素、利奈唑胺、氨苄西林、利福平、四环素、红霉素、环丙沙星的敏感率分别为85.6%、80.7%、49.7%、17.1%、36.4%、7.5%、0.5%。结论:磷霉素对肠球菌有较强的体外抗菌活性,可作为治疗肠球菌感染的首选用药。

Objective:To investigate the antimicrobial activity of fosfomycin and other eight antibiotics against Enterococcus,so as to provide reference for the clinical treatment of Enterococcus infection.Methods:A total of 187 strains Enterococcus were isolated from clinical specimens of hospital patients from Jan 2018 to Dec 2018.Bacteria identities and 8 drug susceptibilities were tested by the BD-phoenix-100,and the antimicrobial susceptibility of fosfomycin was tested by a Kirby-Bauer method.The results were analyzed according to the break points of CLSI 2017.The distribution and antimicrobial susceptibility of pathogens were analyzed by the WHONET 5.6 software.Results:The activity of the 9 antibacterial agents against the 187 Enterococcus(Enterococcus faecium 97 strains,Enterococcus faecalis 86 strains and other 4 strains)showed susceptibilities as follows,vancomycin(100%,except the intrinsic resistance),teicomycin(100%),fosfomycin(85.6%),linezolid(80.7%),ampicillin(49.7%),rifampin(17.1%),tetracyclines(36.4%),erythromycin(7.5%)and ciprofloxacin(0.5%).Conclusion:Fosfomycin is active for Enterococcus in vitro,it can be used as the first-line agent for clinical therapy.